Molxvir 200mg Capsule
Prescription Required
View available alternative with same salt composition
Product introduction
Molxvir 200mg Capsule is the first oral antiviral medication that helps treat mild to moderate COVID-19 in adults. It prevents the virus from multiplying, thereby reducing viral load and disease severity. The drug received emergency use approval from Indian drug regulatory authorities on December 28, 2021.
Molxvir 200mg Capsule is only indicated in patients with mild to moderate COVID-19 symptoms and who have a high risk of developing severe symptoms. The risk factors include obesity, older age (>60 years), diabetes mellitus, and heart diseases. It is not indicated in patients who require immediate hospitalization due to COVID-19. This drug has also been approved by the U.S. Food and Drug Administration (FDA) and the UK regulatory agency for emergency use.
Molxvir 200mg Capsule should be taken orally for no longer than 5 consecutive days. It is important to complete the entire 5 days of treatment, therefore do not stop taking it even if you feel better. The medicine may cause dizziness, headache, diarrhea, and nausea in some patients. If one experiences any such side effects, discuss them with the doctor. They may help with the treatment or suggest ways to prevent them.
Before taking Molxvir 200mg Capsule, let the doctor know if you have any pre-existing medical conditions. To make sure it is safe for you, inform your doctor about all the other medications you are taking. The use of Molxvir 200mg Capsule is not recommended in pregnant women. Pregnant and breastfeeding women should consult with their doctors before taking this medicine.
Molxvir 200mg Capsule is only indicated in patients with mild to moderate COVID-19 symptoms and who have a high risk of developing severe symptoms. The risk factors include obesity, older age (>60 years), diabetes mellitus, and heart diseases. It is not indicated in patients who require immediate hospitalization due to COVID-19. This drug has also been approved by the U.S. Food and Drug Administration (FDA) and the UK regulatory agency for emergency use.
Molxvir 200mg Capsule should be taken orally for no longer than 5 consecutive days. It is important to complete the entire 5 days of treatment, therefore do not stop taking it even if you feel better. The medicine may cause dizziness, headache, diarrhea, and nausea in some patients. If one experiences any such side effects, discuss them with the doctor. They may help with the treatment or suggest ways to prevent them.
Before taking Molxvir 200mg Capsule, let the doctor know if you have any pre-existing medical conditions. To make sure it is safe for you, inform your doctor about all the other medications you are taking. The use of Molxvir 200mg Capsule is not recommended in pregnant women. Pregnant and breastfeeding women should consult with their doctors before taking this medicine.
Uses of Molxvir Capsule
- Herpes labialis
- Genital herpes infection
- Chickenpox
- Herpes Simplex Virus Infections
- Eye infections by Herpes simplex virus
- Chronic hepatitis C virus (HCV) infection
- Treatment of Mild to moderate Coronavirus disease (COVID-19)
Benefits of Molxvir Capsule
In Treatment of Mild to moderate Coronavirus disease (COVID-19)
Molxvir 200mg Capsule helps manage mild to moderate Covid-19 symptoms in those individuals who are at a high risk of developing severe Covid-19 disease and do not need oxygen administration. This medicine may help you recover from the infection if diagnosed early before hospitalization. If you think you have come in contact with a person who has been infected with Covid-19, or if you feel any of these symptoms, consult your doctor immediately.
Side effects of Molxvir Capsule
Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them
Common side effects of Molxvir
- Nausea
- Dizziness
- Diarrhea
How to use Molxvir Capsule
Take this medicine in the dose and duration as advised by your doctor. Molxvir 200mg Capsule may be taken with or without food.
How Molxvir Capsule works
Molxvir 200mg Capsule is an antiviral medicine. It works by inhibiting the SARS-CoV-2 virus from replicating. This stops the virus from producing new copies and hence decreases the viral load in the body.
Safety advice
Alcohol
CONSULT YOUR DOCTOR
It is not known whether it is safe to consume alcohol with Molxvir 200mg Capsule. Please consult your doctor.
Pregnancy
CONSULT YOUR DOCTOR
Molxvir 200mg Capsule is not recommended during pregnancy as there is positive evidence of fetal risk based on animal studies. However, it may still be prescribed by a doctor in situations where the benefits outweigh the risks.
Breast feeding
UNSAFE
Molxvir 200mg Capsule is unsafe to use during breastfeeding. Data suggests that the drug may cause toxicity to the baby.
Driving
UNSAFE
Molxvir 200mg Capsule may decrease alertness, affect your vision, or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Kidney
CAUTION
Molxvir 200mg Capsule should be used with caution in patients with severe kidney disease. Dose adjustment may be needed.
Liver
SAFE IF PRESCRIBED
Molxvir 200mg Capsule is safe to use in patients with liver disease. No dose adjustment is recommended.
What if you forget to take Molxvir Capsule?
If you miss a dose of Molxvir 200mg Capsule, please consult your doctor.
All substitutes
For informational purposes only. Consult a doctor before taking any medicines.
Molxvir 200mg Capsule
₹32.45/Capsule
Molunamax 200 Capsule
J B Chemicals and Pharmaceuticals Ltd
₹55.5/capsule
71% costlier
Cipmolnu 200 Capsule
Cipla Ltd
₹47.95/capsule
48% costlier
Quick tips
- Do not give Molxvir 200mg Capsule to children and adolescents aged less than 18 years.
- Do not stop taking Molxvir 200mg Capsule without talking to your doctor first, as it will protect you from becoming severely ill from COVID-19.
- Even after the treatment, continue practicing COVID-appropriate behavior such as wearing a mask, social distancing, and frequent handwashing.
- For individuals with conceiving potential, it is advisable to use contraceptive methods while taking Molnupiravir and for 4 days after the last dose of the medicine.
- Do not skip any doses and finish the full course of treatment even if you feel better.
- Drink plenty of water while on treatment with this medicine. This helps to prevent dehydration and kidney damage.
- If you have genital herpes, use barrier methods (condoms) for contraception and avoid sexual contact while the sores are present.
- Inform your doctor if you are pregnant or planning to conceive or breastfeeding.
Fact Box
Chemical Class
Nucleoside analoguesues
Habit Forming
No
Therapeutic Class
ANTI INFECTIVES
Action Class
Antiviral Agents (Non-HIV)
Patient concerns
FAQs
Can Molxvir 200mg Capsule be given to children?
No, Molxvir 200mg Capsule is not approved for use in children or patients below the age of 18 years as it may interfere with the growth of bones and cartilage.
What is the advantage of using Molxvir 200mg Capsule?
Molxvir 200mg Capsule has better patient compliance than some other treatment options available against COVID-19. Unlike other medicines that may need a skilled healthcare professional (a doctor or a nurse) to administer, Molxvir 200mg Capsule is an oral medicine that can be consumed by mouth in the dosage and schedule prescribed by the doctor.
Are there any serious risks of taking Molxvir 200mg Capsule?
Yes, there are some serious risks involved with using Molxvir 200mg Capsule, including its potential to cause birth defects in pregnant women and serious damage to the growth of bones and cartilage (which may cause serious muscle damage). Therefore, Molxvir 200mg Capsule should be used only if prescribed by a doctor and not used for self-medication.
Is taking Molxvir 200mg Capsule better than getting vaccinated?
No. There is no comparison between the two, and Molxvir 200mg Capsule is not a substitute for getting vaccinated. Vaccination is for prevention, while Molxvir 200mg Capsule is used to treat an existing COVID-19 infection, provided the infection is diagnosed at an early stage.
Who is at a high risk of developing severe COVID-19?
People who are at a high risk of developing severe COVID-19 include those aged above 60 years, who are obese, have comorbid conditions including high blood pressure, diabetes, asthma, other medical conditions related to the lungs, kidneys (like dialysis patients), liver, or those who have a weak immunity (like cancer patients).
Who should not take Molxvir 200mg Capsule?
Molxvir 200mg Capsule should not be taken to prevent COVID-19 or treat patients hospitalized due to COVID-19. According to the ongoing clinical trials, patients hospitalized with severe COVID-19 infection have not benefited from taking Molxvir 200mg Capsule.
Want to share the information?
Disclaimer:
Tata 1mg's sole intention is to ensure that its consumers get information that is expert-reviewed, accurate and trustworthy. However, the information contained herein should NOT be used as a substitute for the advice of a qualified physician. The information provided here is for informational purposes only. This may not cover everything about particular health conditions, lab tests, medicines, all possible side effects, drug interactions, warnings, alerts, etc. Please consult your doctor and discuss all your queries related to any disease or medicine. We intend to support, not replace, the doctor-patient relationship.References
- Molnupiravir [EMC SmPC]. London, UK: Merck Sharp & Dohme (UK) Limited; 2021. [Accessed 05 Jan. 2022] (online) Available from:
- U.S. Food and Drug Administration: Center for Drug Evaluation and Research FDA Briefing Document, Antimicrobial Drugs Advisory Committee Meeting, November 30, 2021. [Accessed 05 Jan. 2022] (online) Available from:
- Cipla receives Emergency Use Authorisation (EUA) to launch oral anti-viral drug Cipmolnu®(Molnupiravir 200mg) in India for treatment of adult patients with COVID-19, with SpO2>93% and with high risk of disease progression including hospitalization or death. Cipla: Press Statement. [Accessed 05 Jan. 2022] (online) Available from:
- Sun Pharma receives DCGI approval for Molxvir® (Molnupiravir) in India. Sun Pharma: Press Release. [Accessed 05 Jan. 2022] (online) Available from:
- Molnupiravir. U.S. Food & Drug Administration Antimicrobial Drugs Advisory Committee November 30, 2021. [Accessed 05 Jan. 2022] (online) Available from:
- EUnetHTA Rolling Collaborative Review (RCR19) Authoring Team. Molnupiravir for the treatment of COVID-19. Diemen (The Netherlands): EUnetHTA; 2020. Report No.: RCR19, v1.0. [Accessed 05 Jan. 2022] (online) Available from:
- Molnupiravir [Package leaflet: Information for the patient]. London, UK: Merck Sharp & Dohme (UK) Limited; 2021. [Accessed 05 Jan. 2022] (online) Available from:
- European Medicines Agency. Assessment Report: Use of molnupiravir for the treatment of COVID-19. [Accessed 05 Jan. 2022] (online) Available from:
- Kabinger F, Stiller C, Schmitzová J, et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat Struct Mol Biol. 2021;28(9):740-746. [Accessed 05 Jan. 2022] (online) Available from:
- FDA News Release. Coronavirus (COVID-19) Update: FDA Authorizes Additional Oral Antiviral for Treatment of COVID-19 in Certain Adults. December 23, 2021. [Accessed 6th Jan. 2022] (online) Available from:
Marketer details
Name: Sun Pharmaceutical Industries Ltd
Address: Khasra No. 1335-1340,Near EPIP- I, Vill - Bhatoli Kalan ,Baddi, Solan, Himachal Pradesh, 173205 || Plot no 107/108,Namli block , Ranipool, East Sikkim 737135
Country of origin: India
Lab tests offered by us
Related/Popular tests
₹1298
Inclusive of all taxes
MRP₹1425 9% OFF
40.0 capsules in 1 bottle
SOLD OUT
Available alternative with same salt composition
Cipmolnu 200 Capsule
bottle of 40 capsules
by Cipla Ltd
Get by Tomorrow
₹1918
7% off
Molnupiravir (200mg)